50 results about "Lornoxicam" patented technology

The invention relates to the technical field of medicine synthesis, and particularly relates to a synthesis method of lornoxicam. The method comprises the steps of taking 6-chlorine-4-hydroxyl-2-methyl-2-H-thieno[2,3-e]-1,2-thiazine carboxylic acid methyl ester-1,1-dioxide and 2-aminopyridine as raw materials and dimethylbenzene as a solvent, adding a stabilizer, performing heating reflux to perform ammonolysis reaction, reducing the temperature, performing reduced pressure concentration to remove the solvent, adding an organic solvent, pulping, and filtering to obtain a lornoxicam crude product; and refining to obtain the lornoxicam. According to the method, p-toluenesulfonic acid is used as a stabilizer, the reaction temperature is reduced, meanwhile, the reaction is promoted to be carried out forwards, and the product quality and yield are improved; and meanwhile, the dosage of an industrial solvent is reduced, the post-treatment process is optimized, and the three-waste treatment cost is reduced.

The invention relates to a lornoxicam freeze-dried powder injection and a preparation method thereof. The powder injection includes lornoxicam, mannitol and trometamol, and also includes EDTA and a pH regulator, the dosage of the mannitol is 3.5-8.5 grams per gram of lornoxicam, and the dosage of the EDTA is 0.015- 0.025 g / g Lornoxicam. In the present invention, EDTA is used to replace EDTA-disodium salt, and the dosage of EDTA and mannitol is screened at the same time, the clarity of the prepared lyophilized product after reconstitution has been significantly improved, and the formability is good; in addition, the present invention Two kinds of pH regulators are selected. In the preparation process, first use one pH regulator to adjust the solution to a pH value range, then use another pH regulator to adjust the solution to another pH value range, and freeze it. The drying process is strictly controlled, and the stability of the prepared freeze-dried powder injection is significantly improved, and the reconstitution property is good.

The invention discloses a freeze-drying technology for injection lornoxicam. The freeze-drying technology is characterized by sequentially comprising the following steps: (1) conducting pre-freezing; (2) conducting sublimation drying in a mode of six-sectional stepped temperature raising as follows: a, heating up a coolant to a minus (6-4) DEG C, preserving heat for 0.5-1.5h, conducting automatic pulsation to promote air permeation when a vacuum degree is 12-18Pa and stopping the air permeation when the vacuum degree is 22-28Pa; b, heating up the coolant to a temperature ranging from minus 1 DEG C to 1 DEG C, preserving heat for 1-1.5h and conducting pulsation to promote air permeation to 22-28Pa; c, heating up the coolant to 4-6 DEG C, preserving heat for 2-2.5h and conducting pulsation to promote air permeation to 22-28Pa; d, heating up the coolant to 9-11 DEG C, preserving heat for 2-2.5h and conducting pulsation to promote air permeation to 22-28Pa; e, heating up the coolant to 14-16 DEG C, preserving heat for 2-2.5h and conducting pulsation to promote air permeation to 22-28Pa; and f, heating up the coolant to 24-26 DEG C, preserving heat for 1-1.5h and conducting pulsation to promote air permeation to 30-36Pa; and (3) conducting secondary sublimation drying. With the application of the freeze-drying technology provided by the invention, moisture content and impurity limit of the product (the injection lornoxicam) can conform to requirements prescribed within, and meanwhile, the time of an entire freeze-drying process can be also shortened.

The invention relates to a double-layer sustained release lornoxicam tablet which comprises (a) a quick release layer and (b) a sustained release layer, wherein, the quick release layer comprises (a1) the lornoxicam, (a2) alkaline matter and (a3) an other optional carrier or pharmaceutically acceptable excipient and the sustained release layer comprises the (b1) lornoxicam, (b2) sustained releasesubstance and (b3) the other optional carrier or the pharmaceutically acceptable excipient. The weight proportion of (a1) and (b1) is 1:50 to 50:1. The invention also provides a preparation method ofthe double-layer sustained release lornoxicam tablet. The double-layer sustained release preparation of the invention has the advantages of the quick effect of the quick release preparation and the sustained effect of sustained release preparation. In addition, the double-layer sustained release preparation can maintain the effect of effective blood concentration continuously and stably after theeffective blood concentration is reached rapidly.

The invention discloses a lornoxicam compound and a purifying method thereof. In the method, a simple silicagel column chromatography method is used, and a proper stationary phase and a proper mobile phase are used, i.e. silicagel is used as the stationary phase and a mixed solvent of isopropanol and acetone with a certain proportion is used as the mobile phase, the temperature of the column is kept to be higher than the room temperature, and the lornoxicam can be efficiently purified. The method can achieve high yield and high purity, thereby being an effective method for obtaining the lornoxicam with high purity.

The invention discloses a co-crystal of lornoxicam and puerarin, the co-crystal is formed by combining lornoxicam and puerarin at a molar ratio of 1:1, and has a powder X-ray diffraction pattern represented by 2θ angle value , and infrared spectra. The preparation method comprises the steps of: dissolving lornoxicam and puerarin in an organic solvent according to a certain molar ratio, rotating the solvent under reduced pressure, drying in vacuum, and placing it in a resistance furnace to remove the solvent, thereby obtaining lornoxicam puerarin eutectic. The eutectic of the present invention is different from the powder X-ray diffraction and infrared of lornoxicam monomer and puerarin monomer and their physical mixtures, and the crystal form of the eutectic is a new one different from monomers and physical mixtures. Crystal form, improve the compressibility of lornoxicam, and the water solubility of lornoxicam and puerarin.

The invention provides a lornoxicam sustained release tablet and the preparation method thereof. The sustained release tablet includes 2.0-60.00 parts of lornoxicam by weight and 10.00-95.00 parts of sustained release block material by weight; wherein, the sustained release block material includes hydroxypropyl methyl cellulose or compound of hydroxypropyl methyl cellulose and other celluloses. The preparation method is that raw material prescription doses of lornoxicam, sustained release block material and filler are evenly mixed, then added with adhesive to be prepared into soft material; pelletization, drying and finishing granule are carried out according to the conventional technique of the tablet preparation, and the dry grain after finishing granule is added with lubricant, evenly mixed and pressed to make the preparation. Compared with conventional oral lornoxicam preparation, the lornoxicam sustained release tablet can maintain a longer effect after oral administration of thedrug.